This Article Full Text Full Text (PDF) All Versions of this Article: 37/7/1731    most recent 01.STR.0000226465.84561.cbv1 Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Holven, K. B. Articles by Nenseter, M. S. Search for Related Content PubMed PubMed Citation Articles by Holven, K. B. Articles by Nenseter, M. S. Pubmed/NCBI databases Substance via MeSH Related Collections Cerebrovascular disease/stroke Pathophysiology Risk Factors

(Stroke. 2006;37:1731.)
© 2006 American Heart Association, Inc.

Original Contributions

Impaired Inhibitory Effect of Interleukin-10 on the Balance Between Matrix Metalloproteinase-9 and Its Inhibitor in Mononuclear Cells From Hyperhomocysteinemic Subjects

Kirsten B. Holven, PhD; Bente Halvorsen, PhD; Vigdis Bjerkeli, MSc; Jan Kristian Damås, MD, PhD; Kjetil Retterstøl, MD, PhD; Lars Mørkrid, MD, PhD; Leiv Ose, MD, PhD; Pål Aukrust, MD, PhD Marit S. Nenseter, PhD

From the Lipid Clinic (K.B.H., K.R., L.O., M.S.N.), Research Institute for Internal Medicine (K.B.H., B.H., V.B., P.A., J.K.D., M.S.N.), Section of Clinical Immunology and Infectious Diseases (P.A.), and Institute for Clinical Chemistry (L.M.), Rikshospitalet University Hospital, Oslo, Norway.

Correspondence to Kirsten B Holven, Research Institute for Internal Medicine, Rikshospitalet University Hospital, 0027 Oslo, Norway. E-mail kirsten.holven{at}medisin.uio.no

Background and Purpose— Homocysteine has been linked to increased risk of ischemic stroke and other cardiovascular events, but the mechanism by which elevated plasma levels of homocysteine promotes atherogenesis remains unclear. Matrix degradation, partly regulated by the balance between matrix metalloproteinases (MMPs) and tissue inhibitors of MMPs (TIMPs), plays an important role in atherogenesis and plaque destabilization, and we hypothesized an imbalance between MMPs and TIMPs in hyperhomocysteinemia.

Methods— Serum MMP-9 and TIMP-1 was measured in 12 hyperhomocysteinemic and 12 control subjects. The release of MMP-9 and TIMP-1, with and without interleukin-10 (IL-10), and the effect of IL-10 on signal transducer and activator of transcription 3 (STAT3) phosphorylation were measured in peripheral blood mononuclear cells (PBMCs) from hyperhomocysteinemic and control subjects.

Results— Our main findings were: (1) hyperhomocysteinemic subjects had raised serum levels of MMP-9 and MMP-9/TIMP-1 ratio comparing healthy controls; (2) although IL-10 markedly suppressed MMP-9 release from PBMCs in controls, no or only minor effect was seen in hyperhomocysteinemic subjects; (3) although IL-10 enhanced TIMP-1 levels in PBMCs from both hyperhomocysteinemic and control subjects, the increase was more prominent in controls, resulting in a marked difference in IL-10–induced changes in MMP-9/TIMP-1 ratio between these 2 groups; and (4) comparing PBMCs from controls, cells from hyperhomocysteinemic individuals had impaired IL-10–induced STAT3 phosphorylation.

Conclusions— Our findings suggest an attenuated inhibitory response to IL-10 on MMP-9 activity in hyperhomocysteinemic subjects, potentially promoting atherogenesis and plaque instability, representing a novel explanation for increased risk for atherosclerotic disease in these individuals.

Key Words: cytokines • homocysteine • interleukins • risk factors